Topiramate and its clinical applications in epilepsy

Renzo Guerrini, Lucio Parmeggiani

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Topiramate, a derivative of the monosaccharide D-fructose, has shown a wide spectrum of antiepileptic efficacy in both animal models and clinical trials. Multiple putative mechanisms of action include voltage-sensitive sodium channel blockade, calcium channel inhibition, increase of potassium conductance, GABA-mediated chloride current increment, glutamate-mediated neurotransmission inhibition and carbonic anhydrase isoenzyme inhibition. In general, the clinical response is maintained in the long-term. The most common side effects include somnolence, fatigue, headache, psychomotor slowing, confusion, difficulty with memory, impaired concentration and attention, speech and language problems and weight loss. If slowly titrated and used at a low-to-medium dosage, it is well tolerated and offers a valid therapeutic option, the relevance of which is comparable to that of the most widely used 'old' antiepileptic drugs. As it is not yet wholly clear which specific epilepsy syndromes may benefit most from topiramate with respect to other drugs, more accurate indications for initial monotherapy would require syndrome-oriented trials and more clinical experience.

Original languageEnglish
Pages (from-to)811-823
Number of pages13
JournalExpert Opinion on Pharmacotherapy
Volume7
Issue number6
DOIs
Publication statusPublished - Apr 2006

Fingerprint

Epilepsy
Anticonvulsants
Clinical Trials
Confusion
Carbonic Anhydrases
Monosaccharides
Sodium Channels
Calcium Channels
Fructose
Synaptic Transmission
gamma-Aminobutyric Acid
Isoenzymes
Fatigue
Headache
Chlorides
Weight Loss
Glutamic Acid
Potassium
Language
Animal Models

Keywords

  • Antiepileptic drug side effects
  • Antiepileptic drugs
  • Epilepsy treatment
  • Topiramate

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Topiramate and its clinical applications in epilepsy. / Guerrini, Renzo; Parmeggiani, Lucio.

In: Expert Opinion on Pharmacotherapy, Vol. 7, No. 6, 04.2006, p. 811-823.

Research output: Contribution to journalArticle

Guerrini, Renzo ; Parmeggiani, Lucio. / Topiramate and its clinical applications in epilepsy. In: Expert Opinion on Pharmacotherapy. 2006 ; Vol. 7, No. 6. pp. 811-823.
@article{a83f8f7638ed4689801ca60610540ec3,
title = "Topiramate and its clinical applications in epilepsy",
abstract = "Topiramate, a derivative of the monosaccharide D-fructose, has shown a wide spectrum of antiepileptic efficacy in both animal models and clinical trials. Multiple putative mechanisms of action include voltage-sensitive sodium channel blockade, calcium channel inhibition, increase of potassium conductance, GABA-mediated chloride current increment, glutamate-mediated neurotransmission inhibition and carbonic anhydrase isoenzyme inhibition. In general, the clinical response is maintained in the long-term. The most common side effects include somnolence, fatigue, headache, psychomotor slowing, confusion, difficulty with memory, impaired concentration and attention, speech and language problems and weight loss. If slowly titrated and used at a low-to-medium dosage, it is well tolerated and offers a valid therapeutic option, the relevance of which is comparable to that of the most widely used 'old' antiepileptic drugs. As it is not yet wholly clear which specific epilepsy syndromes may benefit most from topiramate with respect to other drugs, more accurate indications for initial monotherapy would require syndrome-oriented trials and more clinical experience.",
keywords = "Antiepileptic drug side effects, Antiepileptic drugs, Epilepsy treatment, Topiramate",
author = "Renzo Guerrini and Lucio Parmeggiani",
year = "2006",
month = "4",
doi = "10.1517/14656566.7.6.811",
language = "English",
volume = "7",
pages = "811--823",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "6",

}

TY - JOUR

T1 - Topiramate and its clinical applications in epilepsy

AU - Guerrini, Renzo

AU - Parmeggiani, Lucio

PY - 2006/4

Y1 - 2006/4

N2 - Topiramate, a derivative of the monosaccharide D-fructose, has shown a wide spectrum of antiepileptic efficacy in both animal models and clinical trials. Multiple putative mechanisms of action include voltage-sensitive sodium channel blockade, calcium channel inhibition, increase of potassium conductance, GABA-mediated chloride current increment, glutamate-mediated neurotransmission inhibition and carbonic anhydrase isoenzyme inhibition. In general, the clinical response is maintained in the long-term. The most common side effects include somnolence, fatigue, headache, psychomotor slowing, confusion, difficulty with memory, impaired concentration and attention, speech and language problems and weight loss. If slowly titrated and used at a low-to-medium dosage, it is well tolerated and offers a valid therapeutic option, the relevance of which is comparable to that of the most widely used 'old' antiepileptic drugs. As it is not yet wholly clear which specific epilepsy syndromes may benefit most from topiramate with respect to other drugs, more accurate indications for initial monotherapy would require syndrome-oriented trials and more clinical experience.

AB - Topiramate, a derivative of the monosaccharide D-fructose, has shown a wide spectrum of antiepileptic efficacy in both animal models and clinical trials. Multiple putative mechanisms of action include voltage-sensitive sodium channel blockade, calcium channel inhibition, increase of potassium conductance, GABA-mediated chloride current increment, glutamate-mediated neurotransmission inhibition and carbonic anhydrase isoenzyme inhibition. In general, the clinical response is maintained in the long-term. The most common side effects include somnolence, fatigue, headache, psychomotor slowing, confusion, difficulty with memory, impaired concentration and attention, speech and language problems and weight loss. If slowly titrated and used at a low-to-medium dosage, it is well tolerated and offers a valid therapeutic option, the relevance of which is comparable to that of the most widely used 'old' antiepileptic drugs. As it is not yet wholly clear which specific epilepsy syndromes may benefit most from topiramate with respect to other drugs, more accurate indications for initial monotherapy would require syndrome-oriented trials and more clinical experience.

KW - Antiepileptic drug side effects

KW - Antiepileptic drugs

KW - Epilepsy treatment

KW - Topiramate

UR - http://www.scopus.com/inward/record.url?scp=33645828611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645828611&partnerID=8YFLogxK

U2 - 10.1517/14656566.7.6.811

DO - 10.1517/14656566.7.6.811

M3 - Article

C2 - 16556095

AN - SCOPUS:33645828611

VL - 7

SP - 811

EP - 823

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 6

ER -